<DOC>
	<DOCNO>NCT01702428</DOCNO>
	<brief_summary>The purpose study evaluate consistency term immune response three different lot GSK Biologicals ' trivalent MMR vaccine manufacture target potency , compare immunogenicity Merck &amp; Co. , Inc. 's MMR vaccine , approve use United States ( US ) .</brief_summary>
	<brief_title>Consistency Study GlaxoSmithKline ( GSK ) Biologicals ' MMR Vaccine ( 209762 ) ( Priorix® ) Comparing Immunogenicity Safety Merck &amp; Co. , Inc. 's MMR Vaccine ( M M R®II ) , Children 12 15 Months Age</brief_title>
	<detailed_description>This study evaluate consistency immune response three different lot GSK Biologicals ' trivalent investigational MMR vaccine ( referred Inv_MMR vaccine , throughout document ) compare immunogenicity US standard care comparator vaccine ( M M R®II , Merck Co. , Inc. , refer Com_MMR throughout document ) child second year life . The Inv_MMR vaccine give one three consistency lot manufacture target potency designate Inv_MMR_L1 , Inv_MMR_L2 Inv_MMR_L3 . The Com_MMR vaccine give one two lot designate Com_MMR_L1 Com_MMR_L2 analyze pooled lot within study . The MMR vaccine co-administered Varivax , Havrix ( US sub-cohort ) Prevnar 13 routinely administer child age US .</detailed_description>
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male female child 12 15 month age time vaccination . The investigator believe parent ( ) Legally Acceptable Representative ( ) ( LAR ( ) ) child , , comply requirement protocol . Written inform consent obtain parent ( ) /LAR ( ) child . Child stable health determine investigator 's clinical examination assessment child 's medical history . For US child : • Child previously receive 3dose series Prevnar 13 ( i.e. , dose give Prevnar/Prevenar ) , last dose least 60 day prior study entry . Child care . Use investigational nonregistered product study vaccine ( ) period start 30 day day study vaccination ( i.e. , 30 day prior Day 0 ) plan use entire study period . Concurrently participate another clinical study , child expose investigational noninvestigational product . Chronic administration immunosuppressant , immunemodifying drug period start 180 day prior first vaccine dose plan administration immunosuppressive immunemodifying drug entire study . For corticosteroid , mean prednisone , ≥0.5 mg/kg/day equivalent . Inhaled topical steroid allow . Planned administration/ administration vaccine foreseen study protocol period start 30 day prior study vaccination Visit 1 end Visit 2 . Please Note : Inactivated influenza ( Flu ) vaccine Haemophilus influenzae type b conjugate vaccine ( Hib ) vaccine may give time , include day study vaccination ( Flu Hib vaccine must administer different location study vaccine/s ) . Any age appropriate vaccine may give start Visit 2 anytime thereafter . Administration immunoglobulins and/or blood product period start 180 day prior study vaccination Visit 1 plan administration date vaccination immunogenicity evaluation Visit 2 . History measles , mumps , rubella , varicella/zoster and/or hepatitis A disease . Known exposure measles , mumps , rubella and/or varicella/zoster period start within 30 day prior first study vaccination . Previous vaccination measles , mumps , rubella , hepatitis A and/or varicella virus . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine , include hypersensitivity neomycin , latex gelatin . Blood dyscrasia , leukemia , lymphomas type , malignant neoplasm affect bone marrow lymphatic system . Acute disease time enrollment . All vaccine administer person minor illness diarrhea , mild upper respiratory infection without fever . Active untreated tuberculosis base medical history . Any condition , opinion investigator , prevents child participate study . For US child : Child previously receive vaccination heptavalent Prevnar/Prevenar ( prior vaccination 3 dos Prevnar 13 ) . Child previously receive fourth dose pneumococcal conjugate vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>15 Months</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Safety</keyword>
	<keyword>Consistency study</keyword>
	<keyword>Measles , mumps rubella disease</keyword>
	<keyword>Healthy child</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>